News

On Tuesday, January 14^th 2025, the kick-off meeting of the European project EU Conversion & PrepHALEU took place at the Representation of the Free State of Bavaria to the EU in Brussels. This ambitious initiative aims to enhance the production and supply of reactor fuel and raw materials essential for medical isotope production.

The PrepHALEU project focuses on establishing an independent supply chain for high assay low enriched uranium (HALEU) within Europe. HALEU is critical for the future of nuclear medicine production, ensuring a stable and reliable supply of isotopes that support healthcare across the continent. For more information on the project’s objectives, visit the LinkedIn post by the project coordinator FRM-II.

NRG PALLAS is proud to participate as a partner in this strategically important project, alongside other irradiators and processors across Europe. The PALLAS-reactor will utilize HALEU for both its fuel and targets for the production of molybdenum-99, a key isotope used in medical imaging. With its contributions, the PALLAS-reactor aims to support treatments for more than 10 million patients annually. Learn more about the PALLAS-reactor at PALLAS (pallasreactor.com).

Representing NRG PALLAS at the meeting were Frodo Klaassen and Ronald Schram, who engaged in discussions about the project’s scope and future impact. NRG PALLAS extends its gratitude to the organizers and chairs for hosting this productive meeting.

This project marks a significant step toward bolstering Europe’s capabilities in nuclear medicine and isotope production, reinforcing its position as a global leader in healthcare innovation.